Novartis preserves India injunction against 'NOVIETS' mark
By Freny Patel ( August 24, 2026, 00:55 GMT | Insight) -- Novartis retained an interim injunction against Noviets Pharma after a division bench of the Delhi High Court found a prima facie risk of confusion between their marks, stressing stricter scrutiny for pharmaceutical trademarks.Global pharmaceutical giant Novartis has retained an interim injunction against Indian rival Noviets Pharma after the Delhi High Court upheld a finding that the rival “NOVIETS” mark was prima facie deceptively similar to “NOVARTIS,” citing heightened public-interest concerns surrounding pharmaceutical trademarks....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.